Is Biomea Fusion Stock a Good Investment?
Biomea Fusion Investment Advice | BMEA |
- Examine Biomea Fusion's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Biomea Fusion's leadership team and their track record. Good management can help Biomea Fusion navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Biomea Fusion's business and its evolving consumer preferences.
- Compare Biomea Fusion's performance and market position to its competitors. Analyze how Biomea Fusion is positioned in terms of product offerings, innovation, and market share.
- Check if Biomea Fusion pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Biomea Fusion's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Biomea Fusion stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Biomea Fusion is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Insignificant | Details | |
Volatility | Very risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Biomea Fusion Stock
Researching Biomea Fusion's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 45.0% of the company shares are held by institutions such as insurance companies. The book value of Biomea Fusion was currently reported as 0.77. The company recorded a loss per share of 3.54. Biomea Fusion had not issued any dividends in recent years.
To determine if Biomea Fusion is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Biomea Fusion's research are outlined below:
| Biomea Fusion is way too risky over 90 days horizon | |
| Biomea Fusion may become a speculative penny stock | |
| Biomea Fusion appears to be risky and price may revert if volatility continues | |
| Biomea Fusion has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (138.43 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Biomea Fusion currently holds about 149.63 M in cash with (119.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.11, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Biomea Fusion has a frail financial position based on the latest SEC disclosures |
Biomea Fusion uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Biomea Fusion. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Biomea Fusion's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of March 2024 Upcoming Quarterly Report | View | |
| 7th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Biomea Fusion's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 105.49 M.Basic technical analysis of Biomea Stock
As of the 20th of July, Biomea Fusion shows the Downside Deviation of 9.06, risk adjusted performance of 0.0656, and Mean Deviation of 6.84. Biomea Fusion technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Biomea Fusion's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Biomea Fusion insiders, such as employees or executives, is commonly permitted as long as it does not rely on Biomea Fusion's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Biomea Fusion insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Biomea Fusion's Outstanding Corporate Bonds
Biomea Fusion issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Biomea Fusion uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Biomea bonds can be classified according to their maturity, which is the date when Biomea Fusion has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Understand Biomea Fusion's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Biomea Fusion's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0656 | |||
| Market Risk Adjusted Performance | (1.08) | |||
| Mean Deviation | 6.84 | |||
| Semi Deviation | 8.47 | |||
| Downside Deviation | 9.06 | |||
| Coefficient Of Variation | 1654.76 | |||
| Standard Deviation | 11.09 | |||
| Variance | 122.95 | |||
| Information Ratio | 0.0477 | |||
| Jensen Alpha | 0.7395 | |||
| Total Risk Alpha | (0.89) | |||
| Sortino Ratio | 0.0584 | |||
| Treynor Ratio | (1.09) | |||
| Maximum Drawdown | 94.78 | |||
| Value At Risk | (10.43) | |||
| Potential Upside | 11.65 | |||
| Downside Variance | 82.11 | |||
| Semi Variance | 71.77 | |||
| Expected Short fall | (8.10) | |||
| Skewness | 2.08 | |||
| Kurtosis | 14.19 |
| Risk Adjusted Performance | 0.0656 | |||
| Market Risk Adjusted Performance | (1.08) | |||
| Mean Deviation | 6.84 | |||
| Semi Deviation | 8.47 | |||
| Downside Deviation | 9.06 | |||
| Coefficient Of Variation | 1654.76 | |||
| Standard Deviation | 11.09 | |||
| Variance | 122.95 | |||
| Information Ratio | 0.0477 | |||
| Jensen Alpha | 0.7395 | |||
| Total Risk Alpha | (0.89) | |||
| Sortino Ratio | 0.0584 | |||
| Treynor Ratio | (1.09) | |||
| Maximum Drawdown | 94.78 | |||
| Value At Risk | (10.43) | |||
| Potential Upside | 11.65 | |||
| Downside Variance | 82.11 | |||
| Semi Variance | 71.77 | |||
| Expected Short fall | (8.10) | |||
| Skewness | 2.08 | |||
| Kurtosis | 14.19 |
Consider Biomea Fusion's intraday indicators
Biomea Fusion intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Biomea Fusion stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Biomea Fusion time-series forecasting models is one of many Biomea Fusion's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Biomea Fusion's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Biomea Stock media impact
There is far too much social signal, news, headlines, and media speculation about Biomea Fusion that are available to investors today. This information is accessible both publicly - through Biomea Fusion's media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Biomea-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Biomea Fusion news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Biomea Fusion relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Biomea Fusion's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Biomea Fusion alpha.
Biomea Fusion Corporate Management
| Juan MD | Chief Officer | Profile | |
| Caroline Dupont | Senior Contracts | Profile | |
| Stephan MD | Chief Officer | Profile | |
| Franco Valle | CFO Officer | Profile | |
| Ravi Upasani | Executive Property | Profile | |
| Ramses Erdtmann | President, CoFounder | Profile | |
| Thomas Butler | Chairman CoFounder | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomea Fusion. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For information on how to trade Biomea Stock refer to our How to Trade Biomea Stock guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomea Fusion. If investors know Biomea will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomea Fusion listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Biomea Fusion is measured differently than its book value, which is the value of Biomea that is recorded on the company's balance sheet. Investors also form their own opinion of Biomea Fusion's value that differs from its market value or its book value, called intrinsic value, which is Biomea Fusion's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomea Fusion's market value can be influenced by many factors that don't directly affect Biomea Fusion's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Biomea Fusion's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Biomea Fusion is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomea Fusion's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.